Compare Charles River Laboratories Intl. Inc (CRL) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs TORM plc — how do they compare? Charles River Laboratories Intl. Inc trades at $229.26 (market cap $11.14B), while TORM plc trades at $29.17 (market cap $3.02B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.7× TORM plc's market cap, and TORM plc pays a 9.52% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | TRMD | |
|---|---|---|
Market Cap | $11.14B | $3.02B |
Sector | Health | Technology |
52-Week High | $233.60 | $34.87 |
52-Week Low | $145.57 | $17.46 |
Enterprise Value | $14.00B | $3.90B |
Dividend Yield | — | 9.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
TRMD trades at $28.86, down 2.1% today, with a bullish technical signal supported by moving averages despite neutral oscillators. The company shows strong fundamentals with a P/E of 8.62, net income margin of 24.41%, and robust cash flow generation. Recent Q1 2026 earnings missed expectations but management raised full-year guidance, highlighting strong freight market conditions and operational execution.
Outlook remains positive with 100% analyst buy ratings and attractive valuation metrics. Key opportunities include the upcoming Q2 2026 earnings report and consistent dividend payments. Risks include earnings volatility, geopolitical impacts on shipping rates, and competitive pressures in the tanker market that could affect future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
